These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 7517409)
1. Effect of zatosetron on ipecac-induced emesis in dogs and healthy men. Schwartz SM; Goldberg MJ; Gidda JS; Cerimele BJ J Clin Pharmacol; 1994 Mar; 34(3):250-4. PubMed ID: 7517409 [TBL] [Abstract][Full Text] [Related]
2. Antagonism of serotonin3 (5-HT3) receptors within the blood-brain barrier prevents cisplatin-induced emesis in dogs. Gidda JS; Evans DC; Cohen ML; Wong DT; Robertson DW; Parli CJ J Pharmacol Exp Ther; 1995 May; 273(2):695-701. PubMed ID: 7752072 [TBL] [Abstract][Full Text] [Related]
3. RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog. Fitzpatrick LR; Lambert RM; Pendley CE; Martin GE; Bostwick JS; Gessner GW; Airey JE; Youssefyeh RD; Pendleton RG; Decktor DL J Pharmacol Exp Ther; 1990 Aug; 254(2):450-5. PubMed ID: 2166791 [TBL] [Abstract][Full Text] [Related]
4. Zatosetron, a 5-HT3 receptor antagonist in a multicenter trial for acute migraine. Chappell AS; Bay JM; Botzum GD; Cohen ML Neuropharmacology; 1994; 33(3-4):509-13. PubMed ID: 7984290 [TBL] [Abstract][Full Text] [Related]
5. Development of high-affinity 5-HT3 receptor antagonists. 2. Two novel tricyclic benzamides. Youssefyeh RD; Campbell HF; Airey JE; Klein S; Schnapper M; Powers M; Woodward R; Rodriguez W; Golec S; Studt W J Med Chem; 1992 Mar; 35(5):903-11. PubMed ID: 1548679 [TBL] [Abstract][Full Text] [Related]
6. Dose-ranging antiemetic evaluation of the serotonin antagonist RG 12915 in patients receiving anticancer chemotherapy. Baltzer L; Kris MG; Tyson LB; Rigas JR; Vreeland F; Pisters KM Cancer; 1993 Nov; 72(9):2695-9. PubMed ID: 8402492 [TBL] [Abstract][Full Text] [Related]
7. Effects of lerisetron, a new 5-HT3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers. Cooper M; Sologuren A; Valiente R; Smith J Arzneimittelforschung; 2002; 52(9):689-94. PubMed ID: 12404884 [TBL] [Abstract][Full Text] [Related]
8. LY277359 maleate: a potent and selective 5-HT3 receptor antagonist without gastroprokinetic activity. Cohen ML; Bloomquist W; Gidda JS; Lacefield W J Pharmacol Exp Ther; 1990 Jul; 254(1):350-5. PubMed ID: 2366187 [TBL] [Abstract][Full Text] [Related]
9. Chronic toxicity of zatosetron, a 5-HT3 receptor antagonist, in rhesus monkeys. Bendele A; Means J; Shoufler J; Schmalz C; Hanasono G; Symanowski J; Adams E Drug Chem Toxicol; 1995 Feb; 18(1):61-82. PubMed ID: 7768200 [TBL] [Abstract][Full Text] [Related]
10. Disposition of zatosetron, a serotonin (5-HT3) receptor antagonist, in humans. Franz PM; Mattiuz EL; Hatcher BL; DeSante KA; Breau AP; Occolowitz JL; Dorman DE; Schmid CR; Goldberg MJ; Rubin A Drug Metab Dispos; 1993; 21(2):249-54. PubMed ID: 8097693 [TBL] [Abstract][Full Text] [Related]
11. The effects of orally administered Y-25130, a selective serotonin3-receptor antagonist, on chemotherapeutic agent-induced emesis. Haga K; Inaba K; Shoji H; Morimoto Y; Fukuda T; Setoguchi M Jpn J Pharmacol; 1993 Nov; 63(3):377-83. PubMed ID: 8107329 [TBL] [Abstract][Full Text] [Related]
12. Mechanisms by which cancer chemotherapeutic drugs induce emesis. Cubeddu LX Semin Oncol; 1992 Dec; 19(6 Suppl 15):2-13. PubMed ID: 1485177 [TBL] [Abstract][Full Text] [Related]
13. Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships. Robertson DW; Lacefield WB; Bloomquist W; Pfeifer W; Simon RL; Cohen ML J Med Chem; 1992 Jan; 35(2):310-9. PubMed ID: 1732548 [TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetic investigation of 5-day multiple dose of tropisetron capsule in patients who had received cisplatin and the usefulness of tropisetron capsule in the treatment of nausea and vomiting]. Suminaga M; Akasaka Y; Nukariya N; Kimura A; Ohtawa M Gan To Kagaku Ryoho; 1995 Aug; 22(9):1209-21. PubMed ID: 7544965 [TBL] [Abstract][Full Text] [Related]
15. Serotonin mechanisms in chemotherapy-induced emesis in cancer patients. Cubeddu LX Oncology; 1996 Jun; 53 Suppl 1():18-25. PubMed ID: 8692546 [TBL] [Abstract][Full Text] [Related]
16. The antiemetic profile of Y-25130, a new selective 5-HT3 receptor antagonist. Fukuda T; Setoguchi M; Inaba K; Shoji H; Tahara T Eur J Pharmacol; 1991 Apr; 196(3):299-305. PubMed ID: 1654255 [TBL] [Abstract][Full Text] [Related]
18. Inhibitory effect of zacopride on Cisplatin-induced delayed emesis in ferrets. Yamakuni H; Nakayama H; Matsui S; Imazumi K; Matsuo M; Mutoh S J Pharmacol Sci; 2006 May; 101(1):99-102. PubMed ID: 16651699 [TBL] [Abstract][Full Text] [Related]
19. Antiemetic activity of the new 5-HT3 antagonist DAU 6215 in animal models of cancer chemotherapy and radiation. Sagrada A; Turconi M; Bonali P; Schiantarelli P; Micheletti R; Montagna E; Nicola M; Algate DR; Rimoldi EM; Donetti A Cancer Chemother Pharmacol; 1991; 28(6):470-4. PubMed ID: 1834359 [TBL] [Abstract][Full Text] [Related]
20. Probable involvement of the 5-hydroxytryptamine(4) receptor in methotrexate-induced delayed emesis in dogs. Yamakuni H; Sawai H; Maeda Y; Imazumi K; Sakuma H; Matsuo M; Mutoh S; Seki J J Pharmacol Exp Ther; 2000 Mar; 292(3):1002-7. PubMed ID: 10688616 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]